Volume | 102,170 |
|
|||||
News | - | ||||||
Day High | 0.93 | Low High |
|||||
Day Low | 0.91 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cardiol Therapeutics Inc | CRDL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.91 | 0.91 | 0.93 | 0.93 | 0.9165 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
277 | 102,170 | $ 0.9269968 | $ 94,711 | - | 0.45 - 1.2353 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:29:41 | formt | 600 | $ 0.91 | USD |
Cardiol Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
82.04M | 65.11M | - | 0 | -30.93M | -0.48 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cardiol Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRDL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.87 | 0.9473 | 0.8501 | 0.8995348 | 82,295 | 0.04 | 4.6% |
1 Month | 0.84 | 0.9473 | 0.72 | 0.8396482 | 98,916 | 0.07 | 8.33% |
3 Months | 1.00 | 1.07 | 0.661 | 0.8786668 | 224,847 | -0.09 | -9.0% |
6 Months | 0.63 | 1.2353 | 0.63 | 0.9207118 | 208,269 | 0.28 | 44.44% |
1 Year | 0.51 | 1.2353 | 0.45 | 0.808293 | 164,199 | 0.40 | 78.43% |
3 Years | 2.63 | 4.96 | 0.45 | 2.11 | 308,025 | -1.72 | -65.4% |
5 Years | 2.63 | 4.96 | 0.45 | 2.11 | 308,025 | -1.72 | -65.4% |
Cardiol Therapeutics Description
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. |